Quick navigation menu :

  1. Go to content
  2. Go to the main sections menu
  3. Go to the search engine
  4. Go to the help menu
  5. Go to the modules
  6. Go to the shortcuts list

Help menu :

  1. Sanofi Worldwide |
  2. Global Business Websites |
  3. Contact Us |
  4. Sitemap |
  5. Help
  1. Font size

    Reduce Increase  

Our Products

Contact Us

sanofi-aventis Pakistan limited

Registered Office

Plot 23, Sector 22
Korangi Industrial Area

Postal Address

P.O. Box 4962

Tel: +92-21-35060221-35

Content :

Telfast® (fexofenadine)


Telfast® Tablet 120 mg 1x10
Telfast® Tablet 180 mg 1x10
Telfast® Tablet 60 mg 1x10

Telfast® D Tablet 1x10

Respiratory disorders

Treatment of the symptoms associated with seasonal allergic rhinitis (SAR) and chronic idiopathic urticaria (CIU) or hives.

New-generation antihistamine

Telfast® is an effective, long-lasting and non-sedating prescription antihistamine that can be taken once or twice daily (depending on dosage and indication) for the treatment of seasonal allergy (hay fever) and hives (chronic idiopathic urticaria). It provides patients with potent relief from the symptoms of allergy without inducing drowsiness.

Sanofi-aventis also markets Allegra-D 12 Hour®, a formulation combined with an extended-release decongestant for effective and non-sedating relief of seasonal allergy symptoms including nasal congestion.

Allegra-D 24 Hour®, a combined antihistamine and decongestant in a single once-daily dose, received FDA approval in October.
The three main markets for Allegra-D 12 Hour® are the U.S. (number 1, with a market share of 49%), Brazil (number 4, 12.5% market share) and Mexico (number 8, 2.4% market share).

Updated April 01, 2006

Module :